BUSINESS SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table is a summary of segment information for the years ended December 31, 2016, 2015 and 2014. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses, and the gains on disposition of businesses associated with the dispositions of Focus Diagnostics and Clinical Trials (see Note 6) . The accounting policies of the segments are the same as those of the Company as set forth in Note 2.

	2016			2015			2014
Net revenues:
DIS business	$	7,138		$	6,965		$	6,873
All other operating segments	377			528			562
Total net revenues	$	7,515		$	7,493		$	7,435
Operating earnings (loss):
DIS business	$	1,244		$	1,118		$	1,068
All other operating segments	64			110			94
General corporate activities	(31		)	171			(179		)
Total operating income	1,277			1,399			983
Non-operating expenses, net	(191		)	(296		)	(160		)
Income from continuing operations before income taxes and equity in earnings of equity method investees	1,086			1,103			823
Income tax expense	(429		)	(373		)	(262		)
Equity in earnings of equity method investees, net of taxes	39			23			26
Income from continuing operations	696			753			587
Income from discontinued operations, net of taxes	—			—			5
Net income	696			753			592
Less: Net income attributable to noncontrolling interests	51			44			36
Net income attributable to Quest Diagnostics	$	645		$	709		$	556

Depreciation and amortization expense for the years ended December 31, 2016, 2015 and 2014 were as follows:

	2016		2015		2014
DIS business	$	170	$	212	$	206
All other operating segments	6		10		13
General corporate	73		82		95
Total depreciation and amortization	$	249	$	304	$	314

Capital expenditures for the years ended December 31, 2016, 2015 and 2014 were as follows:

	2016		2015		2014
DIS business	$	264	$	243	$	283
All other operating segments	21		16		17
General corporate	8		4		8
Total capital expenditures	$	293	$	263	$	308

Net revenues by major service for the years ended December 31, 2016, 2015 and 2014 were as follows:

	2016		2015		2014
Routine clinical testing services	$	4,179	$	4,078	$	4,066
Gene-based and esoteric (including advanced diagnostics) testing services	2,335		2,256		2,158
Anatomic pathology testing services	624		631		649
All other	377		528		562
Total net revenues	$	7,515	$	7,493	$	7,435